Product hub

Product hub: CD34+ haematopoietic stem cells: One cell type, multiple viable sources

Posted: 27 September 2022 | | No comments yet

Learn how you can mobilise CD34+ haematopoietic stem cells and how they can be isolated immediately after collection.

With the recent US Food and Drug Administration (FDA) approval of bluebird bio’s Zynteglo, the first autologous CD34+ based gene therapy for beta thalassemia, haematopoietic stem cells (HSCs) are quickly taking centre stage for advanced therapeutics. BioIVT has more than 35 years’ experience as a biospecimen provider and can deliver the full potential of these cells, from optimal source material such as mobilised leukopaks, bone marrow aspirate and cord blood.


Related organisations